Blood Product Market

Market Overview The Global Blood Product Market is projected to expand significantly, rising from USD 45.23 billion in 2025 to USD 64.27 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.03%. This market involves therapeutic biological substances derived from human blood, such as whole blood, red blood cells, platelets, and plasma, which are essential for transfusion medicine and managing hematological conditions. Its growth is primarily fueled by the increasing worldwide incidence of chronic diseases like cancer and hemophilia, coupled with an aging population requiring more surgical procedures and trauma care. These ongoing factors create a consistent global demand for safe and compatible blood components, irrespective of short-term market fluctuations. However, despite this strong demand, the industry confronts considerable obstacles concerning supply chain reliability and the consistency of voluntary donor participation. Frequent and severe shortages often disrupt the availability of these crucial products, especially during seasonal periods or regional crises, posing substantial operational challenges. For instance, in 2025, America's Blood Centers reported that about 25% of blood centers in the southern United States had a critical supply of less than one day, underscoring the precariousness of maintaining adequate inventory. This situation can hinder sustained market growth and limit patient access to necessary treatments. Market Driver A primary factor propelling the global blood product market is the increasing prevalence of hematological disorders and chronic diseases, which consistently drive demand for whole blood and its components. As conditions like cancer and anemia become more widespread, healthcare systems are under greater pressure to maintain substantial supplies of red blood cells and platelets for supportive care and surgical procedures. For example, the American Cancer Society's 'Cancer Facts & Figures 2025' report, published in January 2025, projected 313,780 new prostate cancer cases in the United States alone, illustrating the growing patient population requiring oncological surgeries and transfusion management. This epidemiological burden, especially within aging populations, guarantees a steady baseline demand for compatible blood products to manage blood loss during surgery and cytopenia induced by chemotherapy, independent of seasonal supply variations. Concurrently, the market is undergoing transformation due to the escalating demand for plasma-derived immunoglobulins, now crucial for treating primary immunodeficiencies and autoimmune neuropathies. This segment demonstrates significantly higher value growth compared to traditional whole-blood transfusions, spurred by improved diagnostic capabilities and more approved uses for immunoglobulin therapies, which necessitate large-scale plasma fractionation. According to a February 2025 Biotech Dispatch article, CSL Behring reported immunoglobulin sales of $3.17 billion in the first half of the fiscal year, marking a 15% increase driven by global patient needs. This particular growth trend reflects the overall vigor of the sector; moreover, Grifols confirmed the robust financial expansion of the global blood product industry, reporting a 10.3% total revenue increase for the full year 2024 in February 2025. Market Challenge The main obstacle hindering the growth of the Global Blood Product Market is the intrinsic volatility within its supply chain and the inconsistent nature of voluntary donor participation. Unlike commercially manufactured drugs, this market is directly dependent on human donation rates, forming a delicate system where product availability frequently falls short of strong clinical requirements. This reliance leads to considerable operational instability, as blood centers strive to uphold steady inventories for essential treatments, consequently impeding revenue growth and market predictability. Declining collection rates disrupt the entire value chain, causing market contraction instead of expansion. This operational vulnerability is demonstrated by recent industry data showing significant inventory shortfalls. For example, the American Red Cross reported that in August 2024, the national blood supply dropped by over 25% in a single month due to seasonal fluctuations in donor activity. Such intense volatility compels healthcare systems to prioritize inventory rationing over service expansion, directly hindering the market's capacity to scale. Therefore, the ongoing disparity between donor turnout and patient demand effectively caps market progression, preventing the sector from fully leveraging the increasing global need for blood therapeutics. Market Trends The Global Blood Product Market is being reshaped by the integration of Pathogen Reduction Technologies (PRT), which are fundamentally enhancing safety standards by proactively inactivating viruses, bacteria, and parasites in blood components. This innovation significantly reduces the risk of transfusion-transmitted infections and is becoming increasingly common for platelets and plasma, shifting the industry's approach from reactive screening to preventative pathogen inactivation to guard against new biological threats. Key industry participants are observing a substantial increase in demand for these enhanced safety features, particularly for fibrinogen complexes vital in hemorrhage control. For instance, Cerus Corporation reported in November 2025 total product revenue of $52.7 million for the third quarter of 2025, a 15% year-over-year increase, largely attributable to the expanded commercial adoption of its INTERCEPT Blood System. Concurrently, the widespread adoption of Automated Blood Collection Systems is significantly improving donor yield and operational efficiency. These systems enable centers to collect specific components such as plasma or platelets in much higher volumes compared to traditional manual methods. These advanced apheresis platforms are crucial for addressing the rising global demand for plasma-derived therapies, effectively mitigating limitations imposed by donor pool constraints through accelerated collection rates. This strategic move towards automated efficiency is underscored by considerable growth in key collection segments, as evidenced by Haemonetics Corporation's plasma business achieving a 19% organic revenue growth in its second-quarter fiscal 2026 earnings release in November 2025, highlighting the rapid market acceptance of its advanced automated collection technologies. Key Market Players * CSL Limited * Takeda Pharmaceutical Company Limited * Octapharma AG * Grifols, S.A. * Kedrion S.p.A * Hualan Biological Vaccine Inc. * Mitsubishi Tanabe Pharma Corporation * Baxter International Inc. * Versiti, Inc. * Bio Products Laboratory Ltd. Report Scope In this report, the Global Blood Product Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Blood Product Market, By Type * Red Blood Cells * Platelets * Fresh Frozen Plasma * White Blood Cells * Others # Blood Product Market, By Application * Blood Station * Hospitals * Others # Blood Product Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Blood Product Market. Available Customizations: Global Blood Product Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).